Global biopharmaceutical firm Merck announced that the company’s Phase III trial for a potential treatment for pneumococcal disease in infants succeeded in meeting key safety, tolerability, and immunogenicity endpoints in the first 30 days.
Swiss drugmakers Roche and Novartis each won European approval for drugs on March 30 in a sign that the rival Basel-based companies are increasingly competing for the same patients.
Swiss drugmaker Roche said 59% of infants with the severest form of spinal muscular atrophy could sit for at least five seconds after getting the company’s medicine Evrysdi for two years, according to trial data, up from 33% after a year of treatment.
Infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during pregnancy does not appear to increase the risk of complications during delivery or negatively impact the health of newborns, according to a new JAMA study.
The U.S. Food and Drug Administration approved an oral treatment from Roche Holding AG and PTC Therapeutics Inc. for spinal muscular atrophy in adults and children two months and above.
The U.S. Food and Drug Administration approved a drug to treat infants and children with HIV, with the drug having been developed by drugmaker GlaxoSmithKline’s HIV drugs division ViiV Healthcare.
Roche company Genentech presented one-year data from FIREFISH Part 2, a pivotal trial of risdiplam in infants one to seven months old with symptomatic Type 1 spinal muscular atrophy (SMA).
Roche company Genentech announced positive top-line results from the pivotal Part 2 of the FIREFISH study looking at risdiplam in infants aged 1-7 months with Type 1 spinal muscular atrophy (SMA).
Novartis AG laid the blame for the manipulation of data behind the company’s $2.1 million gene therapy Zolgensma at the feet of the former executives Brian and Allan Kaspar.
Mallinckrodt Plc tentatively agreed to pay $15.4 million to resolve a U.S. Justice Department probe into how a drugmaker that the company now owns marketed an expensive treatment for a rare infant seizure disorder and multiple sclerosis.